Home LiteratureArticle Details
PMID: 8994421 Published · ppublish English Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem.

Circulation ·Vol. 95 ·No. 1 ·1997-01-07 ·Pages 83-9

Lablanche JM, Grollier G, Lusson JR, Bassand JP, Drobinski G, Bertrand B, Battaglia S, Desveaux B, Juillière Y, Juliard JM, Metzger JP, Coste P, Quiret JC, Dubois-Randé JL, Crochet PD, Letac B, Boschat J, Virot P, Finet G, Le Breton H, Livarek B, Leclercq F, Béard T, Giraud T, Bertrand ME

Abstract

Nitric oxide (NO) donors, in addition to their vasodilator effect, decrease platelet aggregation and inhibit vascular smooth muscle cell proliferation. These actions could have beneficial effects on restenosis after coronary balloon angioplasty. In a prospective multicenter, randomized trial, 700 stable coronary patients scheduled for angioplasty received direct NO donors (infusion of linsidomine followed by oral molsidomine) or oral diltiazem. Treatment was started before angioplasty and continued until 12 to 24 hours before follow-up angiography at 6 months. The primary study end point was minimal lumen diameter, assessed by quantitative coronary angiography, 6 months after balloon angioplasty. Clinical variables were well matched in both groups. However, despite intracoronary administration of isosorbide dinitrate, the reference diameter in the NO donor group was significantly greater than in the diltiazem group on the preangioplasty, postangioplasty, and follow-up angiograms. Pretreatment with an NO donor was associated with a modest improvement in the immediate angiographic result compared with pretreatment with diltiazem (minimum luminal diameter, 1.94 versus 1.81 mm; P = .001); this improvement was maintained at the 6-month angiographic follow-up (minimal lumen diameter, 1.54 versus 1.38 mm; P = .007). The extent of late luminal narrowing did not differ significantly between groups (loss index in the NO donor and diltiazam groups, 0.35 +/- 0.78 and 0.46 +/- 0.74, respectively; P = .103). Restenosis, defined as a binary variable (> or = 50% stenosis), occurred less often in the NO donor group (38.0% versus 46.5%; P = .026). Combined major clinical events (death, nonfatal myocardial infarction, and coronary revascularization) were similar in the two groups (32.2% versus 32.4%). Treatment with linsidomine and molsidomine was associated with a modest improvement in the long-term angiographic result after angioplasty but had no effect on clinical outcome. The improved angiographic result related predominantly to a better immediate procedural result, because late luminal loss did not differ significantly between groups.

MeSH Terms
Aged Angioplasty, Balloon, Coronary Coronary Angiography Coronary Disease/diagnostic imaging,prevention & control,therapy Coronary Vessels/pathology Diltiazem/therapeutic use Drug Therapy, Combination Female Humans Male Middle Aged Molsidomine/analogs & derivatives,therapeutic use Platelet Aggregation Inhibitors/therapeutic use Prospective Studies Recurrence Treatment Outcome Vasodilator Agents/therapeutic use
Chemicals
Platelet Aggregation Inhibitors Vasodilator Agents linsidomine Molsidomine Diltiazem
Authors & Affiliations
25 authors, click to expand affiliations / ORCID
Lablanche J M
Centre Hospitalier Regional et Universitaire, Hôpital Cardiologique, Lille, France.
Grollier G
Lusson J R
Bassand J P
Drobinski G
Bertrand B
Battaglia S
Desveaux B
Juillière Y
Juliard J M
Metzger J P
Coste P
Quiret J C
Dubois-Randé J L
Crochet P D
Letac B
Boschat J
Virot P
Finet G
Le Breton H
Livarek B
Leclercq F
Béard T
Giraud T
Bertrand M E
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
0009-7322
Published
1997-01-07
Pages
83-9
Language
English
Region
United States
NLM ID
0147763
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com